Takeda Pharmaceutical Management
Management criteria checks 2/4
Takeda Pharmaceutical's CEO is Christophe Weber, appointed in Jun 2014, has a tenure of 10.5 years. total yearly compensation is ¥2.08B, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.05% of the company’s shares, worth ¥3.29B. The average tenure of the management team and the board of directors is 7.2 years and 8.5 years respectively.
Key information
Christophe Weber
Chief executive officer
JP¥2.1b
Total compensation
| CEO salary percentage | 15.2% |
| CEO tenure | 10.5yrs |
| CEO ownership | 0.05% |
| Management average tenure | 7.2yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Dec 17
Takeda Pharmaceutical's (TSE:4502) Dividend Will Be ¥98.00
Dec 03Here's Why Takeda Pharmaceutical (TSE:4502) Can Manage Its Debt Responsibly
Nov 25Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 04Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Sep 24Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E
Sep 20Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Aug 08Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 02Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Jul 25Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Jul 11Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year
Jun 30Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt
Jun 11Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings
May 21Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next
May 12Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00
Mar 28Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00
Mar 13Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00
Feb 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | JP¥290b |
| Jun 30 2024 | n/a | n/a | JP¥150b |
| Mar 31 2024 | JP¥2b | JP¥317m | JP¥144b |
| Dec 31 2023 | n/a | n/a | JP¥178b |
| Sep 30 2023 | n/a | n/a | JP¥192b |
| Jun 30 2023 | n/a | n/a | JP¥301b |
| Mar 31 2023 | JP¥2b | JP¥295m | JP¥317b |
| Dec 31 2022 | n/a | n/a | JP¥275b |
| Sep 30 2022 | n/a | n/a | JP¥213b |
| Jun 30 2022 | n/a | n/a | JP¥197b |
| Mar 31 2022 | JP¥2b | JP¥281m | JP¥230b |
| Dec 31 2021 | n/a | n/a | JP¥439b |
| Sep 30 2021 | n/a | n/a | JP¥473b |
| Jun 30 2021 | n/a | n/a | JP¥431b |
| Mar 31 2021 | JP¥2b | JP¥267m | JP¥376b |
| Dec 31 2020 | n/a | n/a | JP¥181b |
| Sep 30 2020 | n/a | n/a | JP¥56b |
| Jun 30 2020 | n/a | n/a | JP¥120b |
| Mar 31 2020 | JP¥2b | JP¥273m | JP¥44b |
| Dec 31 2019 | n/a | n/a | JP¥13b |
| Sep 30 2019 | n/a | n/a | JP¥83b |
| Jun 30 2019 | n/a | n/a | JP¥64b |
| Mar 31 2019 | JP¥2b | JP¥269m | JP¥135b |
| Dec 31 2018 | n/a | n/a | JP¥110b |
| Sep 30 2018 | n/a | n/a | JP¥141b |
| Jun 30 2018 | n/a | n/a | JP¥120b |
| Mar 31 2018 | JP¥1b | JP¥254m | JP¥187b |
Compensation vs Market: Christophe's total compensation ($USD13.21M) is above average for companies of similar size in the JP market ($USD1.36M).
Compensation vs Earnings: Christophe's compensation has increased by more than 20% in the past year.
CEO
Christophe Weber (58 yo)
10.5yrs
Tenure
JP¥2,083,000,000
Compensation
Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.5yrs | JP¥2.08b | 0.050% ¥ 3.3b | |
| Chair of Management Board | no data | no data | no data | |
| CFO & Director | less than a year | no data | 0.00083% ¥ 55.1m | |
| Member of Management Board | no data | no data | no data | |
| Member of Management Board and Head of R&D Global Science & Biomedical Policy | no data | no data | no data | |
| Chief Accounting Officer & Corporate Controller | no data | no data | no data | |
| Senior Vice President of Corporate Finance & Controlling Department | 11.8yrs | no data | no data | |
| Chief Data & Technology Officer | 2.8yrs | no data | no data | |
| Global Head of Investor Relations & Global Finance | 4.3yrs | no data | no data | |
| Global General Counsel | 10.2yrs | no data | no data | |
| Chief Ethics & Compliance Officer | 10.2yrs | no data | no data | |
| Chief Human Resources Officer | 3.9yrs | no data | no data |
7.2yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 4502's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.5yrs | JP¥2.08b | 0.050% ¥ 3.3b | |
| CFO & Director | no data | no data | 0.00083% ¥ 55.1m | |
| President of Research & Development and Representative Director | 9.5yrs | JP¥972.00m | 0.0087% ¥ 579.6m | |
| Independent External Director | 2.5yrs | JP¥32.00m | no data | |
| Independent External Director | 5.9yrs | JP¥44.00m | 0.00026% ¥ 17.3m | |
| Independent External Director | 8.5yrs | JP¥49.00m | 0.00016% ¥ 10.6m | |
| Independent External Director | 8.5yrs | JP¥40.00m | 0.00079% ¥ 52.4m | |
| Independent External Director | 5.9yrs | JP¥44.00m | 0.000070% ¥ 4.6m | |
| Independent External Director | 5.5yrs | JP¥38.00m | no data | |
| Independent External Director | 8.5yrs | JP¥46.00m | no data | |
| Independent External Chair | 3.5yrs | JP¥43.00m | 0.000020% ¥ 1.3m | |
| Independent External Director | 8.5yrs | JP¥43.00m | 0.00063% ¥ 41.8m |
8.5yrs
Average Tenure
66.5yo
Average Age
Experienced Board: 4502's board of directors are considered experienced (8.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 05:25 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Takeda Pharmaceutical Company Limited is covered by 38 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |